Table 3.

Prevalence Rate of MDROs in Nursing Home Residents With Indwelling Devices Following a Targeted Infection Prevention Intervention

Variable	No. of MDROs Isolated (%of Positive Swabs)		Value (95% Cl)
Variable	Intervention Group (n = 154)	Control Group (n = 162)	Cluster-Adjusted Rate Ratio, Algebraic Mean	Cluster- and Covariate-Adjusted Rate Ratio, Algebraic Mean	Cluster- and Covariate-Adjusted Rate Ratio, Geometric Mean
All Indwelling Devices
All MDROs	1299 (26.6)	1732(32.6)	0.67(0.51–0.88)^a	0.65 (0.50–0.85)^a	0.77 (0.62–0.94)^a
MRSA	254(8.2)	323(10.5)	0.92(0.55–1.53)	0.81(0.55–1.18)	0.78 (0.64–0.96)^a
VRE	122 (3.9)	162 (5.3)	1.78(0.68–4.67)	1.81 (0.72–4.55)	1.20(0.82–1.75)
Ceftazidime-resistant GNB	185 (5.4)	295 (8.4)	0.93(0.50–1.72)	0.87(0.49–1.55)	0.94(0.61–1.44)
Ciprofloxacin-resistant GNB	738(19.5)	952 (24.2)	0.94(0.61–1.46)	0.96(0.63–1.47)	0.75 (0.58–0.97)^a
Urinary Catheters
All MDROs	665 (27.0)	784(32.8)	0.64(0.50–0.83)^a	0.94(0.66–1.32)	0.90(0.68–1.21)
MRSA	141 (8.8)	158(11.3)	0.68(0.41–1.14)	0.61 (0.40–0.93)^a	0.71 (0.58–0.86)^a
VRE	53(3.3)	92 (6.6)	1.54(0.60–3.96)	1.45(0.61–3.43)	0.85 (0.58–1.25)
Ceftazidime-resistant GNB	89(5.2)	112 (6.7)	0.65 (0.41–1.02)	0.58(0.39–0.87)	0.57 (0.44–0.74)^a
Ciprofloxacin-resistant GNB	382 (19.8)	422 (23.4)	0.93(0.58–1.49)	0.95(0.60–1.50)	0.96(0.67–1.39)
Feeding Tubes
All MDROs	312(22.2)	429 (26.9)	0.79(0.45–1.38)	0.77(0.45–1.31)	0.91(0.55–1.50)
MRSA	64 (6.4)	86 (8.7)	0.42 (0.22–0.80)^a	0.40(0.26–0.63)^a	0.56(0.38–0.82)^a
VRE	23(2.3)	18(1.8)	1.72(0.34–8.84)	1.72(0.25–11.85)	2.15(0.23–19.90)
Ceftazidime-resistant GNB	29(2.4)	71(6.1)	1.79(0.34–9.44)	2.15(0.79–5.88)	1.24(0.27–5.63)
Ciprofloxacin-resistant GNB	196(16.5)	254(20.1)	0.89(0.52–1.54)	0.89(0.52–1.55)	1.09(0.66–1.79)

Abbreviations: GNB, gram-negative bacilli; MDROs, multi drug-resistant organisms; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci.

P < .05.